Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Revenue of Y-mAbs Therapeutics, Inc. (YMAB)
Revenue in 2023 (TTM): $84.82 M
According to Y-mAbs Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $84.82 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Y-mAbs Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $84.82 M | $73.4 M | $-20,455,000 | $-20,866,000 | $-21,427,000 |
| 2022 | $65.27 M | $57.7 M | $-94,811,000 | $-95,568,000 | $-96,325,000 |
| 2021 | $34.9 M | $32.38 M | $-115,433,000 | $-55,275,000 | $-56,345,000 |
| 2020 | $20.75 M | $18.55 M | $-117,732,000 | $-119,337,000 | $-118,343,000 |
| 2019 | $ | $-166,000 | $-83,004,000 | $-81,028,000 | $-78,886,000 |
| 2018 | $ | $-29,000 | $-43,230,000 | $-43,274,000 | $-43,274,000 |
| 2017 | $ | $ | $-19,244,000 | $-19,161,000 | $-19,161,000 |
| 2016 | $ | $ | $-17,039,000 | $-17,057,000 | $-17,057,000 |